यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - procyclidine hydrochloride - oral tablet - 5mg

यूनाइटेड किंगडम - अंग्रेज़ी - myHealthbox

teva uk limited - aripiprazole - tablets - 5mg - nervous system; psycholeptics; antipsychotics; other antipsychotics - it a is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older

यूनाइटेड किंगडम - अंग्रेज़ी - myHealthbox

teva uk limited - aripiprazole - tablets - 10mg - nervous system; psycholeptics; antipsychotics; other antipsychotics - it a is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.

यूनाइटेड किंगडम - अंग्रेज़ी - myHealthbox

teva uk limited - aripiprazole - tablets - 20mg - nervous system; psycholeptics; antipsychotics; other antipsychotics - it is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.

यूनाइटेड किंगडम - अंग्रेज़ी - myHealthbox

teva uk limited - duloxetine - gastro-resistant capsule, hard - 40mg - psychoanaleptics; other antidepressants - it is indicated for women for the treatment of moderate to severe stress urinary incontinence (sui)

यूरोपीय संघ - अंग्रेज़ी - EMA (European Medicines Agency)

teva b.v.  - docetaxel - head and neck neoplasms; carcinoma, non-small-cell lung; adenocarcinoma; prostatic neoplasms; stomach neoplasms; breast neoplasms - antineoplastic agents - breast cancerdocetaxel teva in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.docetaxel teva in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.docetaxel teva monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy.previous chemotherapy should have included an anthracycline or an alkylating agent.docetaxel teva in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease.docetaxel teva in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.non-small-cell lung cancerdocetaxel teva is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.docetaxel teva in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.prostate cancerdocetaxel teva in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.gastric adenocarcinomadocetaxel teva in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.head and neck cancerdocetaxel teva in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

यूरोपीय संघ - अंग्रेज़ी - EMA (European Medicines Agency)

teva pharma b.v. - pioglitazone hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - pioglitazone is indicated in the treatment of type-2 diabetes mellitus as monotherapy: , in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. , pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance. after initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.,

यूनाइटेड किंगडम - अंग्रेज़ी - myHealthbox

teva uk limited, eastbourne - brinzolamide - eye drops, suspension - 10mg/ml - antiglaucoma preparations and miotics, carbonic anhydrase inhibitors - it is indicated to decrease elevated intraocular pressure in: • ocular hypertension • open-angle glaucoma as monotherapy in adult patients unresponsive to beta-blockers or in adult patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

teva uk limited - ciprofloxacin - solution for infusion - 2 micromol

यूरोपीय संघ - अंग्रेज़ी - EMA (European Medicines Agency)

teva pharma b.v. - pramipexole dihydrochloride monohydrate - parkinson disease - anti-parkinson drugs - pramipexole teva is indicated for treatment of the signs and symptoms of idiopathic parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).pramipexole teva is indicated in adults for symptomatic treatment of moderate to severe idiopathic restless legs syndrome in doses up to 0.54 mg of base (0.75 mg of salt) (see section 4.2).